Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
57.70B | 53.48B | 50.47B | 53.82B | 50.67B | 29.71B | Gross Profit |
21.82B | 19.91B | 18.20B | 18.81B | 18.65B | 9.62B | EBIT |
11.11B | 8.88B | 8.66B | 10.04B | 11.51B | 3.62B | EBITDA |
12.70B | 14.12B | 11.87B | 12.87B | 13.71B | 5.50B | Net Income Common Stockholders |
8.48B | 8.12B | 6.44B | 7.35B | 8.13B | 2.66B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
22.18B | 21.34B | 20.83B | 16.55B | 12.41B | 10.69B | Total Assets |
86.46B | 83.23B | 87.86B | 73.47B | 71.33B | 51.79B | Total Debt |
11.77B | 10.06B | 14.02B | 15.87B | 10.42B | 7.81B | Net Debt |
-10.41B | -11.27B | -6.50B | -673.48M | -1.99B | -2.88B | Total Liabilities |
25.17B | 21.84B | 29.43B | 25.85B | 30.21B | 20.29B | Stockholders Equity |
61.29B | 61.39B | 58.44B | 47.22B | 40.73B | 31.18B |
Cash Flow | Free Cash Flow | ||||
0.00 | 5.33B | 8.00B | 99.81M | 1.13B | 2.62B | Operating Cash Flow |
0.00 | 10.37B | 9.67B | 2.83B | 6.40B | 5.31B | Investing Cash Flow |
0.00 | -4.76B | -2.77B | -2.75B | -6.60B | -2.77B | Financing Cash Flow |
0.00 | -5.13B | -3.52B | 3.96B | 1.93B | -2.24B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $130.16B | 8.28 | 7.01% | 6.21% | 23.36% | 3.63% | |
75 Outperform | ¥128.17B | 15.76 | 13.50% | 1.17% | 5.96% | 26.04% | |
72 Outperform | ¥140.44B | 14.52 | 3.98% | 18.61% | 30.56% | ||
71 Outperform | ¥129.48B | 14.47 | 3.60% | 9.00% | -50.84% | ||
69 Neutral | ¥190.25B | 3.72 | 0.38% | -48.30% | ― | ||
62 Neutral | $11.95B | 9.93 | -7.21% | 4.85% | 7.32% | -8.25% |
Towa Corporation reported a 6% increase in net sales for the fiscal year ending March 31, 2025, with a notable 26% rise in profit attributable to owners of the parent. Despite a decrease in comprehensive income by 68.2%, the company maintained a strong equity-to-asset ratio of 73.8%. The financial results indicate a positive trajectory in sales and profitability, although challenges remain in maintaining comprehensive income levels.
Towa Corporation has announced key personnel changes effective April 1, 2025, involving the reassignment of executive roles within its corporate planning and production divisions. These changes are likely to enhance the company’s strategic planning capabilities and operational efficiency, potentially impacting its market position positively.
Towa Corporation announced a change in its reporting segments, renaming the ‘Fine Plastic Molding Products Business’ to ‘Medical Devices Business’ to better reflect its focus on medical devices. This change is part of the company’s medium-term management plan and will be effective from the fiscal year ending March 2025, with no impact on the classification of reporting segments.
Towa Corporation has announced its second mid-term management plan for 2026-2028, focusing on new challenges and leadership development under the theme ‘Enabling the Next Generation of Leadership with TOWA-ism’. The plan emphasizes enhancing product value, leveraging digital transformation, and investing in human resources to maintain industry leadership. It also outlines strategies for its semiconductor, medical device, and laser businesses, aiming for sustainability and market expansion.
Towa Corporation has developed a new packaging technology called Ultra narrow gap Mold Underfill, designed to enhance semiconductor packaging for next-generation HBM4 semiconductors used in generative AI. This technology allows for improved stacking of semiconductor chips, increasing productivity and quality in manufacturing processes, and is set to be implemented in new equipment with sales beginning in August.